<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126236">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134574</url>
  </required_header>
  <id_info>
    <org_study_id>UF9011</org_study_id>
    <nct_id>NCT02134574</nct_id>
  </id_info>
  <brief_title>Prospective Cohort With Hemopathy in Languedoc-Roussillon</brief_title>
  <acronym>DataDiag2012</acronym>
  <official_title>Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2033</completion_date>
  <primary_completion_date type="Anticipated">June 2033</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Survival with 2 years</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival with 5 years</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival with 10 years</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>hematologic malignancy</arm_group_label>
    <description>hematologic malignancy with a sampling of blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hematologic malignancy</intervention_name>
    <description>hematologic malignancy with a sampling of blood</description>
    <arm_group_label>hematologic malignancy</arm_group_label>
    <other_name>hematologic malignancy with a sampling of blood</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patient for suspected haematological disease and justifying further exploration
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Consultant or hospitalized patient for suspected haematological disease and
             justifying further exploration

          -  Having signed an informed consent

        Exclusion criteria:

          -  Minor or major protected

          -  Patients who have received treatment for hematological pathology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GUILLAUME CARTRON</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie ROUILLE</last_name>
    <email>v-rouille@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology department - UHMontpellier Saint éloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie ROUILLE</last_name>
      <email>v-rouille@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>GUILLAUME CARTRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma,</keyword>
  <keyword>leukemia,</keyword>
  <keyword>multiple myeloma,</keyword>
  <keyword>hodgkin disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
